XKRX:006620 (Korea (the Republic of))
Â
Ordinary Shares
â‚©
4950.00
(-2.75%)
Nov 29
Business Description
Dongkoo Bio&Pharma Co Ltd
ISIN : KR7006620009
Share Class Description:
XKRX:006620: Ordinary SharesCompare
Compare
Traded in other countries / regions
006620.Korea IPO Date
2018-02-13Description
Dongkoo Bio&Pharma Co Ltd is engaged in the research, development, manufacture, and sale of pharmaceuticals products. The company provides products for digestants, other analgesics and antipyretics, nonsteroidal anti-inflammatory drugs, oral hypoglycemic agents, antiplatelet agents, antihistamines and anti-allergic, and decongestants and nasal sprays. It offers its products in multiple forms such as capsules, tablet, powder, granule, and liquid. The company exports its products to various countries including Vietnam, New Zealand, Thailand, Hong Kong and Singapore.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.45 | |||||
| Equity-to-Asset | 0.48 | |||||
| Debt-to-Equity | 0.66 | |||||
| Debt-to-EBITDA | 2.61 | |||||
| Interest Coverage | 7.25 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 2.49 | |||||
| Beneish M-Score | -2.41 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 68.3 | |||||
| 3-Year EBITDA Growth Rate | 65.7 | |||||
| 3-Year EPS without NRI Growth Rate | 61.3 | |||||
| 3-Year Book Growth Rate | 6.1 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 31.92 | |||||
| 9-Day RSI | 37.52 | |||||
| 14-Day RSI | 38.44 | |||||
| 6-1 Month Momentum % | -17.75 | |||||
| 12-1 Month Momentum % | 6.11 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.99 | |||||
| Quick Ratio | 0.59 | |||||
| Cash Ratio | 0.33 | |||||
| Days Inventory | 157.14 | |||||
| Days Sales Outstanding | 29.05 | |||||
| Days Payable | 45.77 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 2.36 | |||||
| Dividend Payout Ratio | 0.35 | |||||
| 3-Year Dividend Growth Rate | 53.3 | |||||
| Forward Dividend Yield % | 2.36 | |||||
| 5-Year Yield-on-Cost % | 2.36 | |||||
| 3-Year Average Share Buyback Ratio | 0.8 | |||||
| Shareholder Yield % | -13.8 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 61.23 | |||||
| Operating Margin % | 7.15 | |||||
| Net Margin % | 6.04 | |||||
| FCF Margin % | -4.33 | |||||
| ROE % | 13.81 | |||||
| ROA % | 7.32 | |||||
| ROIC % | 7.69 | |||||
| ROC (Joel Greenblatt) % | 26.22 | |||||
| ROCE % | 18 | |||||
| Years of Profitability over Past 10-Year | 9 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 9.14 | |||||
| PE Ratio without NRI | 14.71 | |||||
| Price-to-Owner-Earnings | 13.34 | |||||
| PEG Ratio | 0.9 | |||||
| PS Ratio | 0.55 | |||||
| PB Ratio | 1.2 | |||||
| Price-to-Tangible-Book | 1.33 | |||||
| Price-to-Operating-Cash-Flow | 7.36 | |||||
| EV-to-EBIT | 7.91 | |||||
| EV-to-EBITDA | 6.08 | |||||
| EV-to-Revenue | 0.7 | |||||
| EV-to-FCF | -16.32 | |||||
| Price-to-Projected-FCF | 1.38 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.19 | |||||
| Price-to-Graham-Number | 0.92 | |||||
| Earnings Yield (Greenblatt) % | 12.65 | |||||
| FCF Yield % | -8.22 | |||||
| Forward Rate of Return (Yacktman) % | 12.42 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Dongkoo Bio&Pharma Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil â‚©) | 253,710.401 | ||
| EPS (TTM) (â‚©) | 557 | ||
| Beta | 1.03 | ||
| Volatility % | 31.76 | ||
| 14-Day RSI | 38.44 | ||
| 14-Day ATR (â‚©) | 177.182121 | ||
| 20-Day SMA (â‚©) | 5103.5 | ||
| 12-1 Month Momentum % | 6.11 | ||
| 52-Week Range (â‚©) | 4640 - 8990 | ||
| Shares Outstanding (Mil) | 27.04 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Dongkoo Bio&Pharma Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Dongkoo Bio&Pharma Co Ltd Stock Events
| Event | Date | Price(â‚©) | ||
|---|---|---|---|---|
| No Event Data | ||||
Dongkoo Bio&Pharma Co Ltd Frequently Asked Questions
What is Dongkoo Bio&Pharma Co Ltd(XKRX:006620)'s stock price today?
The current price of XKRX:006620 is â‚©4950.00. The 52 week high of XKRX:006620 is â‚©8990.00 and 52 week low is â‚©4640.00.
When is next earnings date of Dongkoo Bio&Pharma Co Ltd(XKRX:006620)?
The next earnings date of Dongkoo Bio&Pharma Co Ltd(XKRX:006620) is .
Does Dongkoo Bio&Pharma Co Ltd(XKRX:006620) pay dividends? If so, how much?
The Dividend Yield %  of Dongkoo Bio&Pharma Co Ltd(XKRX:006620) is 2.36% (As of Today), Highest Dividend Payout Ratio of Dongkoo Bio&Pharma Co Ltd(XKRX:006620) was 0.37. The lowest was 0.07. And the median was 0.32. The  Forward Dividend Yield % of Dongkoo Bio&Pharma Co Ltd(XKRX:006620) is 2.36%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers